These data suggest that the efficacy of anti-FRα antibodies may be impaired by high concentrations of circulating free FRα antigen (as measured in the 8% of ovarian cancer patients with the highest levels of sFRα; see Fig. 4a). Here, FOLR1 is linked to ovarian cancer.